• OPEN AN ACCOUNT
Indian Indices
Nifty
24,868.60 95.45
(0.39%)
Sensex
81,101.32 314.02
( 0.39%)
Bank Nifty
54,216.10 29.20
( 0.05%)
Nifty IT
35,255.95 945.50
( 2.76%)
Global Indices
Nasdaq
45,544.50 122.63
(0.27%)
Dow Jones
6,517.34 14.84
(0.23%)
Hang Seng
43,525.56 -118.25
(-0.27%)
Nikkei 225
9,242.53 21.09
(0.23%)
Forex
USD-INR
88.19 0.04
(0.05%)
EUR-INR
103.31 0.63
(0.62%)
GBP-INR
119.06 0.66
(0.56%)
JPY-INR
0.60 0.00
(0.61%)

EQUITY - MARKET SCREENER

Jaihind Synthetics Ltd
Industry :  Textiles - Processing
BSE Code
ISIN Demat
Book Value()
514312
INE156E01014
17.6287664
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
0
50.42
EPS(TTM)
Face Value()
Div & Yield %
0.03
10
0
 

Cipla's Bengaluru facility receives VAI classification from USFDA
Aug 05,2025
The classification was communicated to the company via email on 4 August 2025. The inspection was conducted under the USFDA’s current Good Manufacturing Practices (cGMP) framework from 26 May to 30 May 2025. In an earlier exchange filing dated May 30, Cipla had disclosed that the inspection concluded with one observation issued in Form 483.

The company reiterated its commitment to compliance and stated that it will work closely with the USFDA to address the observation comprehensively within the stipulated timeframe.

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets.

Cipla reported 10.18% increase in consolidated net profit to Rs 1,297.62 crore on a 3.93% rise in total revenue from operations to Rs 6,957.47 crore in Q1 FY26 over Q1 FY25.

The counter shed 1.42% to Rs 1,494 on the BSE